NE HEALTH BUREAU
HYDERABAD JULY 18
Dr Reddy’s Laboratories Ltd. on Thursday announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited to commercialise Vonoprazan tablets in India. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. Dr. Reddy’s will market Vonoprazan tablets under its own trademark VONO™ to be available in two strengths, 10mg and 20mg.
Pleased to share that we have entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited to commercialise Vonoprazan tablets in India. For over three decades, patients and healthcare professionals have trusted our products in the… pic.twitter.com/K9C9f3Mijn
— Dr. Reddy’s Laboratories Ltd (@drreddys) July 18, 2024
Acid Peptic Disorders (APD), which include Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), are very common in India. A pan-Indian cross-sectional survey of clinicians showed APD prevalence to be in the range of 37-39%. It is more common in the 18-59 age group, with heart burn and epigastric pain as common symptoms .
- Dr Reddy’s will market Vonoprazan tablets under its own trademark VONO™ to be available in two strengths, 10mg and 20mg
- A pan-Indian cross-sectional survey of clinicians showed APD prevalence to be in the range of 37-39%
MV Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s, said, “For over three decades, patients and healthcare professionals have trusted our products in the gastrointestinal segment including well-known brands such as Omez®, Razo™ and others. Leveraging our expertise in this therapy area, we are pleased to make the first-in-class drug Vonoprazan (Vono™) available to patients in India. The non-exclusive patent licensing agreement with Takeda is part of our continuous efforts to make innovative medicines available to patients in India through strategic collaborations to meet unmet needs and enhance standard of care.”
